News | May 06, 2008

GE Licenses Spin Signal Technology to Merck

May 7, 2008 - GE Healthcare signed a nonexclusive agreement with Merck and Co. to provide spin signal technology (SST) for imaging of the lungs to help to advance respiratory treatment development, as part of GE Healthcare’s strategy to accelerate the development of new therapeutics.

GE Healthcare’s drug development strategy includes giving pharmaceutical companies access to novel molecular imaging agents to assess the impact of potential drugs in animal models and, when appropriate, human subjects.

Under terms of the agreement, Merck will be granted access to SST utilizing hyperpolarized Xenon 129 gas, a molecular imaging agent that is under investigation by GE Healthcare to provide high speed, quantitative imaging of the lung using Magnetic Resonance Imaging (MRI). GE Healthcare originally licensed this technology from Princeton University.

This technology is being evaluated to determine if it can provide more sensitive information than currently available tests on how diseased lungs function, by using xenon, a gas that can be modified with the SST to be detectable with MRI. With this technology, MRI delivers images that may provide clinical value by allowing regional imaging of disease. This information could enhance that provided by FEV1, the volume exhaled during the first second of a forced expiratory maneuver.

"Imaging the lungs has traditionally been challenging for pharmaceutical companies needing to assess the impact of developmental therapies on lung function. This agreement enables the companies involved in this collaboration to assess in real-time the effect of potential therapeutics in animal models," said Jonathan Allis, head of the Global Imaging Network at GE Healthcare.

"With cutting edge molecular diagnostic capabilities across all modalities, GE Healthcare is well positioned to work with pharmaceutical companies to tailor therapeutic assessment programs to further their drug development," said Kim Gallagher, head of External Scientific Affairs in the Medical Diagnostics Division of GE Healthcare. "By joining this development collaboration, Merck will have full access to the SST and hyperpolarized Xenon 129 trial data to monitor its potential and plan for its possible incorporation in therapy trials. We look forward to initiating further agreements with key pharmaceutical companies in the coming year in other disease areas."

For more information: www.gehealthcare. com and www.merck.com

Related Content

The FDA has cleared the Toshiba Vantage Galan 3.0T XGO Edition MRI from Canon Medical Systems.
Technology | Magnetic Resonance Imaging (MRI) | February 12, 2018
February 12, 2018 — Physicians now have access to more neuro and cardiac ...
Russian Team Developing New Technology to Significantly Reduce MRI Research Costs
News | Magnetic Resonance Imaging (MRI) | January 16, 2018
January 16, 2018 — Researchers from the NUST MISIS Engineering Center for Industrial Technologies in Russia have deve
Videos | Magnetic Resonance Imaging (MRI) | December 13, 2017
Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of Pitt
GE Healthcare Launches Blanket-Like Air Technology MRI Coils
Technology | Magnetic Resonance Imaging (MRI) | December 13, 2017
GE Healthcare announced U.S. FDA 510(k) clearance of its new Air Technology, what it calls an industry-first suite of...
Toshiba Vantage Galan 3T XGO Edition MRI Features New Advanced Gradient
Technology | Magnetic Resonance Imaging (MRI) | December 11, 2017
Toshiba Medical, a Canon Group company, demonstrated the Vantage Galan 3T XGO Edition with the all-new Saturn X...
Toshiba Launches Vantage Elan Zen Edition MR for Enhanced Patient Comfort
Technology | Magnetic Resonance Imaging (MRI) | December 05, 2017
Toshiba Medical, a Canon Group company, introduced its newest magnetic resonance (MR) system, the Vantage Elan/Zen...
FDA Clears Siemens Magnetom Terra 7T MRI Device

The FDA has cleared the Siemens Magnetom Terra as the first 7T MRI system in the U.S. to gain regulatory approval.

Technology | Magnetic Resonance Imaging (MRI) | October 12, 2017
The U.S. Food and Drug Administration (FDA) cleared the first 7 Tesla (7T) magnetic resonance imaging (MRI) device,...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
MR Solutions took their cryogen-free preclinical multimodality magnetic resonance imaging (MRI) solutions on tour in...
Toshiba Showcases MRI Workflow Enhancements at RSNA 2017
News | Magnetic Resonance Imaging (MRI) | September 21, 2017
September 21, 2017 — Toshiba Medical will highlight its latest...
Overlay Init